Clinical Trials Logo

Filter by:
NCT ID: NCT04864522 Withdrawn - Multiple Myeloma Clinical Trials

Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma

MM FPBMC
Start date: August 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to understand the safety and estimate the efficacy of combining anti-CD3 x anti-SLAMF7 bispecific antibody fresh peripheral blood mononuclear cells (SLAMF7 FPBMC/CS1 FPBMC) for patients with relapsed and/or refractory multiple myeloma. Patients receive 8 weekly doses and then 8 more doses every 2 weeks of SLAMF7 FPBMC by intravenous infusion.

NCT ID: NCT04861441 Withdrawn - Pain, Shoulder Clinical Trials

Continuous Cryotherapy in Shoulder Arthroplasty Patients

Start date: October 22, 2021
Phase: N/A
Study type: Interventional

This is a randomized prospective study to test if cooling therapies decrease narcotic pain medication use in patients following total shoulder replacement surgery (total shoulder arthroplasty, TSA). Postoperative standard care involves use of ice packs placed on the surgical site for periods of approximately 20 minutes every 2 hours, but they do not provide consistent temperature and can become uncomfortably cold. Continuous cryotherapy (CC) machines provide flow of continuous cooled water (45-55° F) via a cuff placed on the affected sight for several hours. There are mixed results as to whether CC is more beneficial than standard ice pack therapy. This study will address whether CC decreases pain and narcotic pain medication use compared to ice pack therapy in TSA patients. The investigators will monitor both patient-reported pain scores and actual narcotic use to test the hypothesis that use of CC reduces postoperative pain and the need for narcotic pain medication. The results of this study may help establish parameters for non-pharmacologic intervention to reduce patient reliance on narcotic medications.

NCT ID: NCT04858620 Withdrawn - Covid19 Clinical Trials

A Study to Evaluate the Efficacy of Xlear vs. Placebo for Acute COVID-19 Infection

Start date: August 30, 2020
Phase: Phase 3
Study type: Interventional

This study aims to find out the efficacy of Xlear nasal spray as an adjunct medication against COVID-19. This encompasses reduction in the number of days to negativization via nasal swab PCR from the average 14 days and early improvement of symptoms.

NCT ID: NCT04858152 Withdrawn - Vitiligo Clinical Trials

Hair Transplantation for Treatment of Vitiligo

Start date: August 1, 2021
Phase: N/A
Study type: Interventional

There are several surgical methods to treat vitiligo patches, and follicular unit extraction (FUE) is one among them. FUE, performed using punch biopsy extraction and hair follicle transplantation, has proven safe and effective in multiple studies for treatment of hair bearing (non-glabrous) skin. This technique has not yet been trialed on hairless areas (glabrous skin) affected by vitiligo, such as the lips, fingertips, knuckles, wrists, and feet, which tend to be resistant to standard treatments. We suspect this technique will be successful in patients who have responded well to other therapies in all areas except for non-hair bearing areas.

NCT ID: NCT04854967 Withdrawn - Clinical trials for Pulmonary Disease, Chronic Obstructive

Pilot Study: Post-Recovery LibEration From Oxygen in Exacerbated COPD

RELIEF Pilot
Start date: April 18, 2022
Phase: N/A
Study type: Interventional

The investigators want to decrease inappropriate oxygen use for patients with COPD. The investigators are testing a new program that will stop oxygen prescriptions for patients that no longer need it and will instead provide them with training in skills that have been shown to help patients breathe better. Participants will be randomly assigned to receive the intervention program or usual care. After 12 weeks the investigators will determine if the program helped stop unnecessary oxygen prescription. The investigators will also determine if health status, distance walked during six minutes, and symptoms of breathlessness after walking are different between participants who received the program and those who did not. The investigators will meet with participating patients and their providers after the study is complete to find out how they feel about this program and if it would be possible to put this change into practice.

NCT ID: NCT04854486 Withdrawn - Covid19 Clinical Trials

Impact of GSE and Xylitol (Xlear) on COVID-19 Symptoms and Time to PCR Negativisation in COVID-19 Patients

Start date: December 16, 2021
Phase: Phase 3
Study type: Interventional

This clinical trial aims to ascertain the impact of GSE and Xylitol (XLEAR) in decreasing the time of negativisation in PCR testing in patients with COVID-19.

NCT ID: NCT04854044 Withdrawn - Clinical trials for Recurrent Glioblastoma

ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma

Start date: May 1, 2021
Phase: Phase 1
Study type: Interventional

This phase I trial studies the effects of ONC201 in combination with standard of care radiation therapy in treating patients with glioblastoma that has come back (recurrent). ONC201 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy photons to kill tumors cells and shrink tumors. Giving ONC201 in combination with radiation therapy may help treat patients with recurrent glioblastoma.

NCT ID: NCT04853355 Withdrawn - Clinical trials for Diabetic Maculopathy

Non-Responsive Diabetic Macular Edema and Spironolactone

Start date: July 2022
Phase: Phase 4
Study type: Interventional

Diabetic patients with macular edema and choroidal hyperpermeability (as manifested as a thick choroid on OCT (optical coherence tomography) and ICG hyperfluorescence on ICG) unresponsive to anti-VEGF (vascular endothelial growth factor) and steroid injections will be treated with spironolactone in addition to the continued treatment of anti-VEGF injections, specifically aflibercept (Eylea).

NCT ID: NCT04849377 Withdrawn - Clinical trials for Head and Neck Squamous Cell Carcinoma (HNSCC)

RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC

Start date: June 14, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to determine the rate of local regional control at 2 years when using de-intensified chemoradiotherapy (CRT) in patients with Human Papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC). Local regional control means no recurrence of the cancer in the head or neck area. Study subjects will be enrolled into 4 groups. Group/treatment will be based on a number of factors, including smoking and drinking history.

NCT ID: NCT04846946 Withdrawn - HIV Infections Clinical Trials

HIV Prevention and PrEP Intervention for SGM Adolescents and Parents: "Hey, Friend"

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

In this 24-month pilot study, we will conduct the preparation phase of a multiphase optimization strategy (MOST) to develop a culturally appropriate (for Deep South contexts, to be adolescent friendly, and to be acceptable to parents or guardians) modular HIV prevention mHealth intervention, targeting behavior change related to HIV testing, HIV prevention knowledge, and pre-exposure prophylaxis (PrEP) uptake for sexual and gender minority (SGM) adolescents, that can be seamlessly integrated into the existing school and community environments across the Deep South.